A5055032084- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Kruppel-like factors research
- Eosinophilic Disorders and Syndromes
- Acute Myeloid Leukemia Research
- Hemoglobinopathies and Related Disorders
- Multiple Myeloma Research and Treatments
- Platelet Disorders and Treatments
- Renal Diseases and Glomerulopathies
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Protein Degradation and Inhibitors
- Cancer Treatment and Pharmacology
- Blood Coagulation and Thrombosis Mechanisms
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Estrogen and related hormone effects
- Cytokine Signaling Pathways and Interactions
- Bone and Joint Diseases
- Studies on Chitinases and Chitosanases
- Chronic Lymphocytic Leukemia Research
- Parvovirus B19 Infection Studies
- Pneumonia and Respiratory Infections
- Respiratory viral infections research
- Hemophilia Treatment and Research
- Neutropenia and Cancer Infections
NU Hospital Group
2016-2025
Uddevalla sjukhus
2013-2025
Nordic Myeloma Study Group
2022
Sahlgrenska University Hospital
2007-2018
Mayo Clinic in Arizona
2017
John Wiley & Sons (United States)
2016
University of Gothenburg
1997-2014
Icahn School of Medicine at Mount Sinai
2014
Clinical Research Consortium
2012
Karolinska University Hospital
2011
Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and alleviation of this burden represents a paramount treatment objective in the development MPN-directed therapies. We aimed assess utility an abbreviated symptom score for most pertinent representative MPN subsequent serial use assessing response therapy.The Neoplasm Symptom Assessment Form total (MPN-SAF TSS) was calculated as mean 10 items from two previously validated scoring systems. Questions focus on fatigue,...
Purpose Patients with myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, have a propensity to develop acute myeloid leukemia (AML) myelodysplastic syndromes (MDSs). Using population-based data from Sweden, we assessed the role of MPN treatment subsequent AML/MDS risk special focus on leukemogenic potential hydroxyurea (HU). Methods On basis nationwide cohort (N = 11,039), conducted nested case-control study, 162 patients...
The role of antiplatelet therapy as primary prophylaxis thrombosis in low-risk essential thrombocythemia has not been studied randomized clinical trials. We assessed the benefit/risk low-dose aspirin 433 patients with (271 a CALR mutation, 162 JAK2V617F mutation) who were on or observation only. After follow up 2215 person-years free from cytoreduction, 25 thrombotic and 17 bleeding episodes recorded. In CALR-mutated patients, did affect risk but was associated higher incidence (12.9 versus...
The Philadelphia negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and myelofibrosis, are associated with substantial vascular transformative complications. Standard therapy for high-risk disease, particularly in patients that have failed initial therapy, remains controversial. Non-pegylated interferon has previously been shown to be effective controlling erythrocytosis, thrombocytosis thrombotic complications, but was found poor tolerability...
Summary Three hundred and twenty‐seven patients from two population‐based cohorts with an established diagnosis of polycythaemia vera were studied for prognostic risk factors survival leukaemia in a long‐term survey. The relative ( RS ) was 72% 46% at 10 20 years respectively, the time diagnosis. Multivariate analysis identified age >70 years, white blood cell count >13 × 9 /l thrombo‐embolism as independent factors. Patients or three these had year 26%, compared 59% 84% one no...
The Philadelphia chromosome-negative (Ph-) chronic myeloproliferative neoplasms include the three well-known clinical entities polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Over time, patients with ET PV may develop (MF), all carry a risk of transformation into acute myeloid leukemia (AML). In population-based survey during 1983-1999, we studied total 358 who were diagnosed in city Gothenburg, Sweden. At time diagnosis, evaluable bone marrow biopsy...
Summary Inhibition of histone deacetylases may be an important target in patients with myeloproliferative neoplasms. This investigator‐initiated, non‐randomized, open‐label phase II multi‐centre study included 63 (19 essential thrombocythaemia, 44 polycythaemia vera) from 15 centres. The primary objective was to evaluate if vorinostat followed by a decline clonal myeloproliferation as defined E uropean L eukaemia N et. Thirty (48%) completed the intervention period (24 weeks therapy). An...
ABSTRACT Whereas patients with multiple myeloma (MM) have a well-documented susceptibility to infections, this has been less studied in other B-cell disorders, such as Waldenstrom's macroglobulinemia (WM) and monoclonal gammopathy of undetermined significance (MGUS). We investigated the humoral immunity 24 different pathogens elderly MM ( n = 25), WM 16), MGUS 18) age-matched controls 20). Antibody titers against pneumococci, staphylococcal alpha-toxin, tetanus diphtheria toxoids, varicella,...
Purpose Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) associated with disabling symptoms and heightened risk of life-threatening complications. Recent studies have demonstrated the effectiveness JAK inhibitor therapy in patients PV who history prior hydroxyurea (HU) use (including resistance or intolerance), phlebotomy requirements, palpable splenomegaly. We aimed to determine how these features contribute alone aggregate symptom burden. Patients Methods Through prospective...
The myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and myelofibrosis, are distinguished by their debilitating symptom profiles, life-threatening complications profound impact on quality of life. role gender plays in the symptomatology neoplasms remains under-investigated. In this study we evaluated how relates to patients' characteristics, disease overall expression. A total 2,006 patients (polycythemia vera=711, thrombocythemia=830, myelofibrosis=460,...
Abstract Background The reported incidence of Philadelphia‐negative myeloproliferative neoplasms (MPNs) differs substantially between previous reports, likely due to true regional differences in and/or variations the quality and coverage cancer registers. Objective We therefore assessed MPN Sweden during recent years using prospectively collected information captured Swedish health Methods Patients with MPNs were identified through Cancer Register Blood 2000 2014. Information on population...
The Philadelphia chromosome-negative (Ph-) chronic myeloproliferative disorders (MPD) have an inherent tendency for transformation into acute myelogenous leukaemia (AML). long-term rate of leukaemic in unselected MPD patients was studied well-defined populations Gothenburg, Sweden and the Côte d'Or area, Burgundy, France, respectively. Over a median observation time 15 yr, 56 subjects (7%) out total 795 with Ph- transformed to AML. yearly incidence AML 0.38% polycythaemia vera (PV), 0.37%...
The quality of life (QoL) at the time diagnosis myeloproliferative neoplasm (MPN) has, to date, not been studied. One hundred and seventy-nine patients with MPN: 80 essential thrombocythemia (ET), 73 polycythemia vera (PV), 22 primary myelofibrosis (PMF) four MPN undifferentiated, were included in this study. European Organisation for Research Treatment Cancer Quality Life Questionnaire Core 30 (EORTC-QLQC30) MPN-Symptom Assessment Form (MPN-SAF) used evaluate QoL. Fatigue was most reported...
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) is a validated quality of life (QoL) instrument. In our Swedish cohort 114 patients the symptomatic burden was found to be severe, with fatigue reported in 88% and reduced QoL majority patients. Patients primary myelofibrosis had highest scores, low QoL, for most MPN-SAF items, compared polycythemia vera essential thrombocythemia. Higher age showed significant associations BFI (Brief Fatigue Inventory) score, early satiety,...
Abstract. Objective. In the literature incidence rates for chronic Philadelphia chromosome negative (Ph‐) myeloproliferative disorders (MPD) are known to vary extensively; only a few studies have, however, been concerned with trends over time. Therefore, aim of present work was investigate possible as regards time Ph‐MPD. Design. Herein, we carried out retrospective population‐based survey on polycythaemia vera (PV), essential thrombocythae‐mia (ET) and idiopathic myelofibrosis (IMF), in...
Allogeneic haematopoietic stem cell transplantation remains the only curative treatment of myelofibrosis with myeloid metaplasia (MMM). Previous reports have indicated significant treatment-related mortality (TRM) for patients transplanted after myeloablative conditioning but superior survival has been reported reduced-intensity (RIC). We report results a survey all allogeneic transplantations MMM performed in Sweden at six transplant units between 1982 and 2004. Twenty-seven were...
Thalidomide and bortezomib have been frequently used for second-line therapy in patients with myeloma relapsing after or refractory to initial melphalan-based treatment, but no randomized trials published comparing these two treatment alternatives.Thalidomide- bortezomib-naïve melphalan were randomly assigned low-dose thalidomide + dexamethasone (Thal-Dex) (Bort-Dex). At progression on either therapy, the offered crossover alternative drug combination. An estimated 300 would be needed trial...